GynecologyGynecologyГинекология2079-56962079-5831Consilium Medicum28639ArticlesСтатьиReview ArticlePersonal selection of hormonal contraceptionПерсональный подбор гормональной контрацепцииKuznetsovaI VКузнецоваИ В

д-р мед. наук, проф., проф. каф. акушерства и гинекологии №1 лечебного фак-та ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова»

ms.smith.ivk@gmail.comI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России15082017194VOL 19, NO4 (2017)ТОМ 19, №4 (2017)364309042020Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://gynecology.orscience.ru/2079-5831/article/view/28639

Hormonal contraception is a highly effective means of protecting against unwanted pregnancy and has been widely used throughout the world for more than 50 years. Unfortunately, in Russia, women still do not often use hormonal contraceptives as residents of Europe, North and South America. One of the reasons for the lack of proper distribution of hormonal contraceptives in our country remains insufficient awareness of the useful properties of contraception, along with an exaggerated view of the negative consequences of taking hormones, as well as a lack of time for the medical worker to provide adequate counseling. To overcome this problem, it is necessary to create easy-to-use algorithms of the practitioner's actions that help to simplify and optimize the choice of hormonal contraceptive for each specific woman depending on her health status, reproductive status and age. This publication contains an example of such an algorithm, including options for prescribing oral contraceptive drugs for different groups of women.

Гормональная контрацепция является высокоэффективным средством предохранения от нежеланной беременности и широко применяется во всем мире уже более 50 лет. К сожалению, в России женщины по-прежнему не столь часто прибегают к использованию гормональных контрацептивов, как жительницы Европы, Северной и Южной Америки. Одной из причин отсутствия должного распространения гормональных противозачаточных средств в нашей стране остаются недостаточная осведомленность о полезных свойствах контрацепции наряду с преувеличенным представлением о негативных последствиях приема гормонов, а также недостаток времени у медицинского работника на адекватное консультирование. Для преодоления этой проблемы необходимо создавать легкие в использовании алгоритмы действий практикующего врача, помогающие максимально упростить и оптимизировать выбор гормонального контрацептивного средства для каждой конкретной женщины в зависимости от состояния ее здоровья, репродуктивного статуса и возраста. В данной публикации содержится пример подобного алгоритма, включающего варианты назначения оральных контрацептивных препаратов для разных групп женщин.

hormonal contraceptioncombined oral contraceptivestherapeutic effects of hormonal contraceptionchloromadinonedienogestdrospirenonedesogestrelgestodeneгормональная контрацепциякомбинированные оральные контрацептивылечебные эффекты гормональной контрацепциихлормадинондиеногестдроспиренондезогестрелгестоденSitruk-Ware R, Nath A, Mishell D.R. Contraception technology: past, present and future. Contraception 2013; 87 (3): 319-30.Veljković́ M, Veljković́ S. The risk of breast, cervical, endometrial and ovarian cancer in oral contraceptive users. Med Pregl 2010; 63 (9-10): 657-61.Dossus L, Allen N, Kaaks R et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010; 127 (2): 442-51.Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010; 82 (3): 221-9.Schindler A.E. Non - contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab 2013; 11 (1): 41-7.Weill A, Dalichampt M, Raguideau F et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016; 353: i2002.Mayeda E.R, Torgal A.H, Westhoff C.L. Weight and Body Composition Changes During Oral Contraceptive Use in Obese and Normal Weight Women. J Womens Health (Larchmt) 2014; 23 (1): 38-43.Blum R.W, Astone N.M, Decker M.R et al. A conceptual framework for early adolescence: A platform for research. Int J Adolesc Med Health 2014; 26: 321e31.Anttila L, Bachmann G, Hernadi L et al. Contraceptive efficacy of a combined oral contraceptive containing ethinylestradiol 20 mg/drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis of four open - label studies. Eur Obstet Gynecol Reprod Biol 2011; 155 (2): 180-2.Dinger J, Minh T.D, Buttmann N et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117: 33-40.Dinger J.C, Heinemann L.A, Kuhl-Habich D. The safety of a drospirenone - containing oral contraceptive: Final results from the European active surveillance study on oral contraceptives based on 142, 475 women - years of observation. Contraception 2007; 75: 344-54.Lidegaard Ø, Løkkegaard E, Svendsen A.L, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow - up study. BMJ 2009; 339: b2890.Reid R.L, Westhoff C, Mansour D et al. Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117-22.Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: A review of two recently published studies. J Fam Plann Reprod Health Care 2010; 36: 33-8.Szarewski A, Mansour D, Shulman L.P. 50 years of ‘The Pill’: Celebrating a golden anniversary. J Fam Plann Reprod Health Care2010; 36: 231-8.Van Hylckama Vlieg A, Helmerhorst F.M, Vandenbroucke J.P et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the MEGA case - control study. BMJ 2009; 339: b2921.Rothman K.J, Wise L.A, Sørensen H.T et al. Volitional Determinants and Age - related Decline in Fecundability: A General Population Prospective Cohort Study in Denmark. Fertil Steril 2013; 99 (7): 1958-64.Holinka C.F, Brincat M, Coelingh Bennink H.J.T. Preventive effect of oral estetrol in a menopausal hot flash model. Climacteric 2008; 11 (Suppl. 1): 15-21.Coelingh Bennink H.J.T, Heegaard A-M, Visser M et al. Oral bioavailability and bone - sparing effects of estetrol in an osteoporosis model. Climacteric 2008; 11 (Suppl. 1): 2-14.Kannis J.A, Adams J, Borgström F et al. The cost - effectiveness of alendronate in the management of osteoporosis. Bone 2008; 42 (1): 4-15.Allali F, Mansouri L, Abourazzak F et al. The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women. BMC Women’s Health 2009; 9: 31.Bonafede M.M, Miller J.D, Lukes A.S et al. Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs. Clinin Econom Outcom Res 2014; 6: 423-9.Allen R.H, Cwiak C.A. Contraception for midlife women. Menopause 2016; 23 (1): 183-91.Che Y, Liu X, Zhang B, Cheng L. Oral contraception following abortion: A systematic review and meta - analysis. Medicine (Baltimore) 2016; 95 (27): e3825.Mueck A.O. Dinogest: an oral progestogen for the treatment of endometriosis. Expert Rev Obstet Gynecol 2011; 6 (1): 5-15.Hall K.S, Trussell J, Schwarz E.B. Progestin - only contraceptive pill use among women in the United States. Contraception 2012; 86 (6): 653-8.Virkus R.A, Løkkegaard E.C, Bergholt T et al. Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. A national cohort study. Thromb Haemost 2011; 106 (2): 304-9.Practice Bulletin. Noncontraceptive Uses of Hormonal Contraceptives. Obstet Gynecol 2010; 15 (1): 206-18.Caruso S, Iraci M, Cianci S et al. Comparative, open - label prospective study on the quality of life and sexual function of women affected by endometriosis - associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest 2016; 8: 923-31.ACOG Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol 2013; 122: 176-85.ACOG. Management of acute abnormal uterine bleeding in non - pregnant women. Committee Opinion № 557. Obstet Gynecol 2013; 121: 891-6.Munro M.G et al. for the FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Intern J Gynecol Obstet 2011; 113: 3-13.SOGC. Abnormal Uterine Bleeding in Pre - Menopausal Women 2013; 35 (5; Suppl. 1): 1-28.Подзолкова Н.М., Кузнецова И.В. Применение марвелона в пролонгированном режиме в качестве противорецидивной терапии гиперпластических процессов эндометрия. Акуш. и гинекол. 2007; 1: 53-7.Chandra V, Kim J.J, Benbrook D.M et al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol 2016; 27 (1): e8.Карахалис Л.Ю., Федорович О.К., Басина И.Б., Червонная И.Ю. Влияние патогенетически обоснованной терапии аденомиоза на его течение. Эффективная фармакотерапия. 2009; 5: 18-24.Toxqui L, Perez-Granados A.M, Blanco-Rojo R et al. A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and gynecological parameters in young women. BMC Women’s Health 2014; 14: 71.Gierisch J.M, Coeytaux R.R, Urrutia R.P et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013; 22 (11): 1931-43.Goodman N.F, Cobin R.H, Futterweit W et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - part 1. Endocr Pract 2015; 21 (11): 1291-300.Arowojolu A.O, Gallo M.F, Lopez L.M, Grimes D.A. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7: CD004425.Рагимова З.Э., Каиль-Горячкина М.В. Междисциплинарные аспекты андроген - зависимой дермопатии (обзор литературы) // Дерматология. Приложение к журналу Consilium Medicum. 2016; 3: 56-62.Naessé́n S, Carlströ̈m K, Byströ̈̈m B et al. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology 2007; 32 (5): 548-54.Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab 2013; 27 (1): 13-24.Bäckström T, Haage D, Löfgren M et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 2011; 191: 46-54.Brown J, O’Brien P.M.S, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.Bitzer J, Paoletti A.M. Added benefits and user satisfaction with a low - dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin Drug Invest 2009; 29 (2): 73-8.Аганезова Н.В., Линде В.А. Клинический опыт применения комбинированного монофазного орального контрацептива с дроспиреноном при синдроме предменструального напряжения. Проблемы репродукции. 2008; 1: 66-72.Сасунова Р.А., Межевитинова Е.А. Предменструальный синдром // Гинекология. 2007; 9 (6): 34-8.Rapkin A.J. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729-41.Breech L.L, Braverman P.K. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. Int J Womens Health 2009; 1: 85-95.Геворкян М.А., Манухина Е.И., Смирнова С.О., Кузнецова Е.М. Профилактика формирования функциональных кист (клиническая лекция). Эффективная фармакотерапия. 2015.Moorman P.G, Havrilesky L.J, Gierisch J.M et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high - risk women: a systematic review and meta - analysis. J Clin Oncol 2013; 31: 4188-98.Havrilesky L.J, Gierisch J.M, Moorman P.G et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013; 212: 514.Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-14.Havrilesky L.J, Moorman P.G, Lowery W.J et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta - analysis. Obstet Gynecol 2013; 122: 139-47.Mantha S, Karp R, Raghavan V et al. Assessing the risk of venous thromboembolic events in women taking progestin - only contraception: a meta - analysis. BMJ 2012; 14: e4944.Табеева Г.Р., Громова С.А. Эстрогены и мигрень. Неврологический журн. 2009; 5: 45-53.